Table 3 Baseline characteristics of patients with high titers (OD ≥ 0.40) of anti-PF4/heparin antibody
From: Reduced induction of anti-PF4/heparin antibody in RA patients after total knee arthroplasty
Rheumatoid arthritis | Osteoarthritis | |||||
|---|---|---|---|---|---|---|
Postoperative seroconversion (OD ≥ 0.4) | Postoperative seroconversion (OD ≥ 0.4) | |||||
Positive | Negative | Positive | Negative | |||
(n = 3) | (n = 23) | p value | (n = 25) | (n = 73) | p value | |
Gender (male/female) | 0/3 | 2/21 | 0.5950 | 6/19 | 12/61 | 0.286 |
Age (years), mean ± SD | 67.7 ± 9.5 | 70.0 ± 805 | 0.6289 | 74.6 ± 6.1 | 74.3 ± 6.1 | 0.598 |
Disease duration (years) | 14.0 ± 10.1 | 13.2 ± 8.2 | 0.7734 | |||
BMI (kg/m2) | ||||||
Mean ± SD | 25.2 ± 1.0 | 25.8 ± 5.0 | 0.9360 | 27.5 ± 4.0 | 26.7 ± 4.0 | 0.628 |
History of venous thrombosis, n (%) | 1 (33.3 %) | 2 (8.7 %) | 0.2090 | 0 | 4 (5.5 %) | 0.301 |
Comorbidities | ||||||
Hypertension | 2 (66.7 %) | 18 (78.3 %) | 0.6539 | 17 (68.0 %) | 49 (67.1 %) | 0.936 |
Ischemic heart disease | 0 | 0 | 2 (8.0 %) | 4 (5.5 %) | 0.482 | |
Diabetes | 1 (33.3 %) | 6 (26.1 %) | 0.7901 | 8 (32.0 %) | 14 (19.2 %) | 0.185 |
Cerebrovascular disease | 1 (33.3 %) | 1 (4.3 %) | 0.0764 | 2 (8.0 %) | 6 (8.2 %) | 0.669 |
Operation time (min) | ||||||
Mean ± SD | 88.0 ± 4.4 | 94.6 ± 22.4 | 0.8096 | 91.4 ± 21.8 | 94.4 ± 24.2 | 0.699 |
RF (titer IU/ml) | 1/3 (17.3 ± 24.8) | 14/23 (59.8 ± 73.7) | 0.5558 0.1366 | N/a | N/a | |
Anti-CCP Ab (titer U/ml) | 0/3 (0.6 ± 0.0) | 18/23 (246.2 ± 560.1) | 0.0215 0.0209 | N/a | N/a | |
CRP (mg/dl) | 1.51 ± 1.09 | 1.24 ± 1.37 | 0.3086 | N/a | N/a | |
Use of steroid | 2 (66.7 %) | 16 (69.6 %) | 0.9185 | N/a | N/a | |
Use of MTX | 1 (33.3 %) | 9 (39.1 %) | 0.8461 | N/a | N/a | |
Foot pump | 2 (66.7 %) | 11 (47.8 %) | 0.5393 | 10 (40.0 %) | 36 (49.3 %) | 0.421 |